A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78803
Title:
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Authors:
Howell, Anthony ( 0000-0002-3879-5991 ) ; Robertson, John F R; Vergote, I
Abstract:
Tumors that have spread to the liver or lungs (visceral metastases) are associated with a worse prognosis than tumors in soft tissue and bone only. Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases. We include data from Phase III clinical trials, comparing clinical benefit (CB) with anastrozole versus tamoxifen as a first-line treatment, and versus megestrol acetate (MA) or fulvestrant as a second-line therapy. Patients in these trials had adequate organ function and the volume of disease had to be minimal or moderate for them to be eligible for inclusion. First-line treatment of patients with or without visceral metastases in the overall population resulted in CB rates of 49.5 and 62.3%, respectively, for anastrozole and 46.9 and 55.9%, respectively, for tamoxifen. In patients with confirmed hormone receptor (HR)-positive tumors, the CB rate was 51.9 and 65.7%, respectively, for anastrozole and 41.6 and 58.7%, respectively, for tamoxifen. In patients with or without visceral metastases, second-line treatment with anastrozole resulted in a CB rate of 31.4 and 51.8%, respectively, compared with 31.9 and 47.1%, respectively, for those treated with MA. Patients in the overall population with and without visceral metastases treated with anastrozole obtained a CB rate of 37.4 and 43.8%, respectively, while those treated with fulvestrant obtained a CB rate of 38.2 and 47.6%, respectively. In patients with confirmed HR-positive tumors, CB was seen in 37.6 and 41.5%, respectively, of patients treated with anastrozole and in 37.3 and 47.0%, respectively, of patients treated with fulvestrant. The results reveal anastrozole to be an effective and valuable first- and second-line therapy in postmenopausal women with ABC and visceral metastases, showing similar CB to other endocrine therapies.
Affiliation:
Cancer Research UK Department of Medical Oncology, Christie CRC Research Hospital, Christie Hospital National Health Service Trust, University of Manchester, Manchester, UK. maria.parker@christie-tr.nwest.nhs.uk
Citation:
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. 2003, 82 (3):215-22 Breast Cancer Res. Treat.
Journal:
Breast Cancer Research and Treatment
Issue Date:
Dec-2003
URI:
http://hdl.handle.net/10541/78803
DOI:
10.1023/B:BREA.0000004375.17920.0b
PubMed ID:
14703069
Type:
Article
Language:
en
ISSN:
0167-6806
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthony-
dc.contributor.authorRobertson, John F R-
dc.contributor.authorVergote, I-
dc.date.accessioned2009-08-27T09:39:36Z-
dc.date.available2009-08-27T09:39:36Z-
dc.date.issued2003-12-
dc.identifier.citationA review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. 2003, 82 (3):215-22 Breast Cancer Res. Treat.en
dc.identifier.issn0167-6806-
dc.identifier.pmid14703069-
dc.identifier.doi10.1023/B:BREA.0000004375.17920.0b-
dc.identifier.urihttp://hdl.handle.net/10541/78803-
dc.description.abstractTumors that have spread to the liver or lungs (visceral metastases) are associated with a worse prognosis than tumors in soft tissue and bone only. Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases. We include data from Phase III clinical trials, comparing clinical benefit (CB) with anastrozole versus tamoxifen as a first-line treatment, and versus megestrol acetate (MA) or fulvestrant as a second-line therapy. Patients in these trials had adequate organ function and the volume of disease had to be minimal or moderate for them to be eligible for inclusion. First-line treatment of patients with or without visceral metastases in the overall population resulted in CB rates of 49.5 and 62.3%, respectively, for anastrozole and 46.9 and 55.9%, respectively, for tamoxifen. In patients with confirmed hormone receptor (HR)-positive tumors, the CB rate was 51.9 and 65.7%, respectively, for anastrozole and 41.6 and 58.7%, respectively, for tamoxifen. In patients with or without visceral metastases, second-line treatment with anastrozole resulted in a CB rate of 31.4 and 51.8%, respectively, compared with 31.9 and 47.1%, respectively, for those treated with MA. Patients in the overall population with and without visceral metastases treated with anastrozole obtained a CB rate of 37.4 and 43.8%, respectively, while those treated with fulvestrant obtained a CB rate of 38.2 and 47.6%, respectively. In patients with confirmed HR-positive tumors, CB was seen in 37.6 and 41.5%, respectively, of patients treated with anastrozole and in 37.3 and 47.0%, respectively, of patients treated with fulvestrant. The results reveal anastrozole to be an effective and valuable first- and second-line therapy in postmenopausal women with ABC and visceral metastases, showing similar CB to other endocrine therapies.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectLiver Canceren
dc.subjectLung Canceren
dc.subjectCancer Metastasisen
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshBreast Neoplasms-
dc.subject.meshClinical Trials, Phase III as Topic-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLiver Neoplasms-
dc.subject.meshLung Neoplasms-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshNitriles-
dc.subject.meshPostmenopause-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshTreatment Outcome-
dc.subject.meshTriazoles-
dc.titleA review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie CRC Research Hospital, Christie Hospital National Health Service Trust, University of Manchester, Manchester, UK. maria.parker@christie-tr.nwest.nhs.uken
dc.identifier.journalBreast Cancer Research and Treatmenten
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.